SNS Financial Group LLC Purchases 271 Shares of Johnson & Johnson (NYSE:JNJ)

SNS Financial Group LLC increased its stake in shares of Johnson & Johnson (NYSE:JNJ) by 4.2% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 6,798 shares of the company’s stock after purchasing an additional 271 shares during the period. SNS Financial Group LLC’s holdings in Johnson & Johnson were worth $1,127,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently made changes to their positions in the stock. Lantz Financial LLC raised its stake in shares of Johnson & Johnson by 3.3% in the first quarter. Lantz Financial LLC now owns 11,974 shares of the company’s stock valued at $1,986,000 after acquiring an additional 377 shares during the period. Sulzberger Capital Advisors Inc. purchased a new position in shares of Johnson & Johnson in the 4th quarter worth approximately $453,000. Joel Isaacson & Co. LLC grew its position in shares of Johnson & Johnson by 3.5% in the 1st quarter. Joel Isaacson & Co. LLC now owns 74,132 shares of the company’s stock worth $12,294,000 after buying an additional 2,526 shares during the last quarter. State of Wyoming boosted its stake in Johnson & Johnson by 205,580.0% in the 4th quarter. State of Wyoming now owns 10,284 shares of the company’s stock worth $1,487,000 after purchasing an additional 10,279 shares in the last quarter. Finally, Range Financial Group LLC lifted its stake in Johnson & Johnson by 18.9% during the 1st quarter. Range Financial Group LLC now owns 15,886 shares of the company’s stock valued at $2,635,000 after acquiring an additional 2,529 shares during the period. 69.55% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Trading Up 0.4%

NYSE JNJ traded up $0.67 during trading on Friday, hitting $163.65. 9,764,459 shares of the company’s stock traded hands, compared to its average volume of 8,138,165. The stock has a fifty day moving average of $154.29 and a two-hundred day moving average of $154.97. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.26 and a quick ratio of 1.03. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $169.99. The firm has a market cap of $393.75 billion, a P/E ratio of 17.50, a PEG ratio of 2.18 and a beta of 0.41.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, beating the consensus estimate of $2.68 by $0.09. The company had revenue of $23.74 billion during the quarter, compared to the consensus estimate of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 33.07%. The firm’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same quarter last year, the firm earned $2.82 earnings per share. As a group, sell-side analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th will be given a $1.30 dividend. The ex-dividend date of this dividend is Tuesday, August 26th. This represents a $5.20 annualized dividend and a dividend yield of 3.18%. Johnson & Johnson’s payout ratio is presently 55.61%.

Analyst Ratings Changes

A number of research firms have recently issued reports on JNJ. Leerink Partners lowered shares of Johnson & Johnson from an “outperform” rating to a “market perform” rating and dropped their target price for the stock from $169.00 to $153.00 in a report on Tuesday, May 13th. The Goldman Sachs Group upgraded shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and upped their target price for the stock from $157.00 to $172.00 in a research note on Wednesday, April 9th. Royal Bank Of Canada raised their target price on shares of Johnson & Johnson from $181.00 to $185.00 and gave the stock an “outperform” rating in a research report on Thursday. Raymond James Financial decreased their price target on Johnson & Johnson from $165.00 to $162.00 and set an “outperform” rating for the company in a report on Monday, April 14th. Finally, Sanford C. Bernstein reissued a “market perform” rating on shares of Johnson & Johnson in a report on Wednesday, April 16th. Eleven investment analysts have rated the stock with a hold rating, nine have given a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and a consensus target price of $172.87.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.